Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest appraisals from NICE include the rejection of Herceptin use in gastric cancer but give positive recommendations to RoActemra and TNF-inhibitors in rheumatoid arthritis.
You may also be interested in...
NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?
U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.
NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?
U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.
Sanofi-Aventis Receives Positive Final NICE Guidance On Multaq
U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.